selinexor: Clinical Trials

183 trials of selinexor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 completed, 35 recruiting, 26 active not recruiting, 23 terminated. 114 Phase 2, 76 Phase 1, 19 Phase 3, 5 Not applicable, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2114Recruiting 26, Completed 21, Terminated 18, Active not recruiting 17, Not yet recruiting 11, Unknown 10, Withdrawn 10, Enrolling by invitation 1
Phase 176Completed 33, Recruiting 11, Terminated 9, Unknown 8, Active not recruiting 7, Withdrawn 7, Not yet recruiting 1
Phase 319Recruiting 6, Active not recruiting 5, Completed 4, Not yet recruiting 2, Terminated 1, Unknown 1
Not applicable5Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1
Early Phase 11Withdrawn 1
Phase 41Unknown 1

Follow selinexor: new trials by email Literature Review of selinexor trials Research Report on selinexor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
Phase 2Not yet recruitingDana-Farber Cancer Institute602026-12-012026-09-21
The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
Selinexor - Myeloid Tumors
Not applicableNot yet recruitingBing Han302026-11-012026-06-08
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 2RecruitingJohn Mascarenhas262026-10-232026-10-27
New Genotype-guided Treatment in Newly Diagnosed PTCL
Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL)
Phase 1 / Phase 2Not yet recruitingRuijin Hospital1082026-07-012026-07-16
Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms
Selinexor - Myeloproliferative Neoplasms
Phase 2Not yet recruitingZhongshan Hospital (Xiamen), Fudan University152026-07-012026-06-04
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.2552026-06-112026-09-17
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Glofitamab combined with selinexor - Diffuse Large B-Cell Lymphoma (DLBCL)
Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine302026-06-102026-06-25
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
TQB2934 injection, Pomalidomide Capsule, Selinexor tablets - Multiple Myeloma
Phase 3Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.2602026-06-012026-05-08
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma
Phase 1 / Phase 2RecruitingNatalie Callander622026-05-212026-08-31
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma
Phase 2Not yet recruitingBeijing Tongren Hospital342026-05-152026-04-28
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
Sintilimab, Pegaspargase, Selinexor - NKTCL
Phase 2Not yet recruitingSun Yat-sen University472026-05-062026-05-08
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Selinexor - Multiple Myeloma
Phase 1RecruitingWashington University School of Medicine202026-03-172026-10-15
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3RecruitingShandong New Time Pharmaceutical Co., LTD2612026-01-252026-05-12
Golidocitinib Combined With Selinexor for CAEBVD
golidocitinib, Selinexor (combination therapy) - Lymphohistiocytosis, EBV
Phase 2 / Phase 3RecruitingBeijing Friendship Hospital282026-01-012026-01-27
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Selinexor, azacitidine - NK T-Cell Lymphoma
Phase 2Not yet recruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine392025-12-302025-12-11
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
QLS32015, Pomalidomide, Selinexor - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.2282025-11-072026-05-22
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Selinexor, Anlotinib, DLL3 CAR-NK cells - Extensive Stage Lung Small Cell Cancer
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital1652025-11-012025-09-30
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Selinexor 40 mg - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Phase 2RecruitingDuke University272025-08-222026-09-03
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
Selinexor, Thalidomide (100mg), Dexamethasone - Langerhans Cell Histiocytosis (LCH)
Phase 2Active not recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences402025-08-012025-10-02
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma
Phase 3RecruitingChengdu Zenitar Biomedical Technology Co., Ltd3902025-07-182025-09-19

Showing 20 of 183. Sign in to see all of them.

Conditions studied

Multiple Myeloma (48)  ·  Leukemia, Myeloid, Acute (26)  ·  Recurrence (26)  ·  Lymphoma, Large B-Cell, Diffuse (14)  ·  Sarcoma (9)  ·  Endometrial Neoplasms (6)  ·  Lymphoma (6)  ·  Primary Myelofibrosis (6)  ·  Glioblastoma (5)  ·  Lymphoma, T-Cell, Peripheral (5)  ·  Myelodysplastic Syndromes (5)  ·  Neoplasm Metastasis (5)  ·  Neoplasms, Plasma Cell (5)  ·  Ovarian Neoplasms (5)  ·  Colorectal Neoplasms (4)

Sponsors

Karyopharm Therapeutics Inc (34)  ·  H. Lee Moffitt Cancer Center and Research Institute (6)  ·  National Cancer Institute (NCI) (5)  ·  Ruijin Hospital (5)  ·  St. Jude Children's Research Hospital (5)  ·  Institute of Hematology & Blood Diseases Hospital, China (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  University Health Network, Toronto (4)  ·  Antengene Corporation (3)  ·  National University Hospital, Singapore (3)  ·  Sun Yat-sen University (3)  ·  The First Affiliated Hospital of Soochow University (3)  ·  University of Chicago (3)  ·  Washington University School of Medicine (3)  ·  Weill Medical College of Cornell University (3)

Countries

United States (90)  ·  China (52)  ·  Canada (21)  ·  Spain (19)  ·  Germany (16)  ·  Israel (14)  ·  France (13)  ·  Belgium (12)  ·  Greece (11)  ·  Italy (11)  ·  Denmark (10)  ·  United Kingdom (10)  ·  Poland (9)  ·  Australia (8)  ·  Austria (6)

Top investigators

Albiruni Razak, M.D. (2)  ·  Erin Bertino, MD (2)  ·  Hongtao Liu (2)  ·  Jeffrey E. Rubnitz, MD,PhD (2)  ·  A P Chen (1)  ·  Abdulraheem Yacoub, MD (1)  ·  Adam L Green (1)  ·  Alice Mims, MD (1)  ·  Amar Gajjar, MD (1)  ·  Amit Mahipal, M.D. (1)  ·  Andrew B Lassman, MD (1)  ·  Andrew E Place, MD,PhD (1)  ·  Andrzej Jakubowiak (1)  ·  Anna Spreafico (1)

Results publications

PMID 27507877, PMID 31433920, PMID 32589977, PMID 37393120, PMID 38826786, PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23752175, PMID 23753028, PMID 23927993, PMID 24743138, PMID 25934708, PMID 27458288, PMID 27557643, PMID 28148715, PMID 28188133, PMID 28336527, PMID 28468797, PMID 28630120, PMID 29155058, PMID 29203585, PMID 29304833, PMID 29381435, PMID 29437609, PMID 29487219, PMID 29610030, PMID 29654631, PMID 29773601, PMID 30345906, PMID 30352784, PMID 30610226, PMID 30689707, PMID 30881137, PMID 30996012, PMID 31124580, PMID 31545113, PMID 31822399, PMID 31831564, PMID 32487143, PMID 32598257, PMID 32735836, PMID 33023948, PMID 33148342, PMID 33189178, PMID 33202794, PMID 33528286, PMID 33755235, PMID 33764240

NIH funding

2017 (3), P30CA014599 (3), 2014 (2), 2023 (2), 2015 (1), 2019 (1), P01CA108671 (1), P30CA012197 (1), P30CA015083 (1), P30CA022453 (1), P30CA046934 (1), P30CA093373 (1), P50CA097274 (1), P50CA100632 (1), U10CA180886 (1)